Search Results - "Padmanabhan, Swami"
-
1
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
Published in Journal of clinical oncology (01-04-2010)“…New treatments are needed for patients with fludarabine- and alemtuzumab-refractory (FA-ref) chronic lymphocytic leukemia (CLL) or patients with…”
Get full text
Journal Article -
2
Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study
Published in Haematologica (Roma) (01-08-2015)Get full text
Journal Article -
3
Current status of therapy for chronic myeloid leukemia: a review of drug development
Published in Future oncology (London, England) (01-06-2008)“…Chronic myeloid leukemia (CML) has led the way for developing rational drug development in cancer. Most cases of CML diagnosed and treated in chronic phase are…”
Get more information
Journal Article -
4
Protein Kinase C βII Plays an Essential Role in Dendritic Cell Differentiation and Autoregulates Its Own Expression
Published in The Journal of biological chemistry (05-08-2005)“…Dendritic cells (DC) arise from a diverse group of hematopoietic progenitors and have marked phenotypic and functional heterogeneity. The signal transduction…”
Get full text
Journal Article -
5
Analysis of Donor Age and Absolute Lymphocyte Count Recovery as Prognostic Indicators of Survival after Allogeneic Blood or Marrow Transplantation
Published in Blood (16-11-2006)“…Absolute lymphocyte count (ALC) recovery ≥500 cells/mL at day 15 or 30 post-autologous (autoBMT) transplantation has been reported in many studies as an…”
Get full text
Journal Article -
6
The Adaptor Protein SLP-76 Is Not a Direct Substrate for BCR-ABL in the Chronic Myeloid Leukemia Cell Line K562
Published in Blood (16-11-2004)“…SLP-76(SH2 domain-containing leukocyte protein of 76 kD) is a hematopoietic adapter protein that is expressed in myeloid and T cells. SLP-76 is a substrate for…”
Get full text
Journal Article -
7
Incidence, Clinical Presentation and Outcome of Secondary Multiple Extramedullary Plasmacytomas: Experience at Roswell Park Cancer Institute
Published in Blood (16-11-2006)“…Introduction: Extramedullary plasmacytomas are malignant plasma cell tumors that arise outside of the bone marrow. They occur either as solitary tumors with a…”
Get full text
Journal Article -
8
Aggressive relapse of multiple myeloma with intracerebral extension and associated hemorrhage
Published in Leukemia & lymphoma (01-01-2007)Get full text
Journal Article -
9
Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab
Published in BLOOD (20-11-2009)“…Abstract 3433 Poster Board III-321 Monoclonal antibody (mAb) therapies represent an important clinical advance for patients (pts) with CLL, yet little is known…”
Get full text
Journal Article Conference Proceeding -
10
Pro-Apoptotic Effect of Lenalidomide (L) in Patients with Chronic Lymphocytic Leukemia (CLL) Is Possibly Mediated through Interruption of the Phosphatidylinositol Pathway
Published in Blood (16-11-2006)“…Introduction: In a phase II clinical trial we reported the antileukemic effect of L in CLL pts. In this clinical trial 24/34 (70.5%) pts with detectable tumor…”
Get full text
Journal Article -
11
Human leukocyte antigen DR4 is associated with inferior progression-free survival following allogeneic hematopoietic stem cell transplantation for lymphoid malignancies
Published in Leukemia & lymphoma (01-01-2008)“…The Class II human leukocyte antigen (HLA) DRB1 antigen DR4 is associated with autoimmune disorders and response to cyclosporine immunosuppression in…”
Get full text
Journal Article -
12
Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors
Published in Cancer chemotherapy and pharmacology (01-01-2013)“…Purpose Omacetaxine mepesuccinate is a first-in-class cephalotaxine demonstrating clinical activity in chronic myeloid leukemia. A subcutaneous (SC)…”
Get full text
Journal Article -
13
Protein Kinase C βII Plays an Essential Role in Dendritic Cell Differentiation and Autoregulates Its Own Expression
Published in The Journal of biological chemistry (05-08-2005)“…Dendritic cells (DC) arise from a diverse group of hematopoietic progenitors and have marked phenotypic and functional heterogeneity. The signal transduction…”
Get full text
Journal Article -
14
Protein kinase C betaII plays an essential role in dendritic cell differentiation and autoregulates its own expression
Published in The Journal of biological chemistry (05-08-2005)“…Dendritic cells (DC) arise from a diverse group of hematopoietic progenitors and have marked phenotypic and functional heterogeneity. The signal transduction…”
Get full text
Journal Article -
15
Bridging the gap in hematological malignancies
Published in Expert review of hematology (01-06-2012)“…After the success of the BTG Series in Singapore in 2010 and 2011, meeting organizers held the 3rd International Hematologic Malignancies Conference in Hong…”
Get more information
Journal Article -
16
Ofatumumab, a Novel CD20 Monoclonal Antibody, Is Active in Patients With Fludarabine- and Alemtuzumab-Refractory or Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia Irrespective of Prior Rituximab
Published in CLINICAL LYMPHOMA & MYELOMA (01-12-2009)“…Ofatumumab, a novel CD20 monoclonal antibody, produces high response rates regardless of prior rituximab exposure in patients with fludarabine- and…”
Get full text
Journal Article Conference Proceeding -
17
Aggressive relapse of multiple myeloma with intracerebral extension and associated hemorrhage
Published in Leukemia & lymphoma (01-06-2007)Get full text
Report